Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,386,099 papers from all fields of science
Search
Sign In
Create Free Account
leridistim
Known as:
14-125 interleukin-3(14-alanine, 50-aspartic acid), granulocyte colony stimulating factor(17-serine) fusion protein
, MPO
, Myelopoietin
A recombinant chimeric dual G-CSF and IL-3 receptor agonist. Leridistim binds with high affinity to both the interleukin-3 (IL-3) and granulocyte…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (3)
Granulocyte Colony-Stimulating Factor
Interleukin-3
Recombinant Fusion Proteins
myelopoietin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
model of radiation-induced myelosuppression stimulates multilineage hematopoietic recovery in a nonhuman primate Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist,
T. MacVittie
,
A. Farese
,
Walter G. Smith
,
C. Baum
,
E. Burton
,
P. John
2013
Corpus ID: 91461411
2008
2008
Novel biomarkers--the long march from bench to bedside.
Michael A Weber
,
C. Hamm
European Heart Journal
2008
Corpus ID: 20090122
In recent years, a deeper understanding of the pathobiology of atherothrombosis as the underlying mechanism of acute coronary…
Expand
2008
2008
[Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma…
M. Klabusay
,
D. Lysák
,
V. Hrabčáková
,
M. Navrátil
,
P. Čoupek
,
J. Mayer
Casopis lekaru ceskych
2008
Corpus ID: 7835638
BACKGROUND Peripheral blood stem cells are the preferred source for transplantation of hematopoiesis in patients with non-Hodgkin…
Expand
2004
2004
Preparative and analytical chromatography of pegylated myelopoietin using monolithic media.
T. Hall
,
D. C. Wood
,
Christine E. Smith
Journal of Chromatography A
2004
Corpus ID: 24888733
2002
2002
Cytokine-based treatment of radiation injury: potential benefits after low-level radiation exposure.
T. MacVittie
,
A. Farese
Military Medicine
2002
Corpus ID: 34986470
The use of growth factors (GFs) in the treatment of radiation injury has focused on enhancing recovery from acute radiation…
Expand
2002
2002
The enhanced in vitro hematopoietic activity of leridistim, a chimeric dual G-CSF and IL-3 receptor agonist
A. Abegg
,
L. Vickery
,
+11 authors
W.Gary Smith
Leukemia
2002
Corpus ID: 8624328
The in vitro activity of leridistim was characterized for cell proliferation, generation of colony-forming units (CFU) and…
Expand
2001
2001
Phage display mutagenesis of the chimeric dual cytokine receptor agonist myelopoietin
S. Lee
,
R. Ibdah
,
+6 authors
J. McKearn
Leukemia
2001
Corpus ID: 20138145
Myelopoietins comprise a class of chimeric cytokine receptor agonists consisting of an hIL-3 (human interleukin-3) receptor…
Expand
2001
2001
Bivalent binding and signaling characteristics of Leridistim, a novel chimeric dual agonist of interleukin-3 and granulocyte colony-stimulating factor receptors.
J. Monahan
,
W. Hood
,
J. Welply
,
J. Shieh
,
J. Polazzi
,
X. Li
Experimental Hematology
2001
Corpus ID: 2171179
Review
2000
Review
2000
Synthetic cytokines containing interleukin-3 exert potent megakaryopoietic activity.
N. Ahmed
,
M. Khokher
,
H. Hassan
Haematologia
2000
Corpus ID: 42493772
The shared properties of haematopoietic cytokines and their receptors have enabled the genetically engineered construction of…
Expand
1999
1999
Circular permutation of the granulocyte colony-stimulating factor receptor agonist domain of myelopoietin.
C. A. Mcwherter
,
Y. Feng
,
+10 authors
J. Mckearn
Biochemistry
1999
Corpus ID: 13161341
Myelopoietins (MPOs) are a family of engineered dual interleukin-3 (IL-3) and granulocyte colony-stimulating factor (G-CSF…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE